Skip to main content

Plasma Protein Binding (PPB) evaluation for GalNAc-conjugated small interfering RNA (siRNA)

The plasma protein binding (PPB) evaluation for GalNAc-conjugated small interfering RNA (siRNA) is an important parameter in understanding its pharmacokinetics (PK), distribution, and clearance from the body. GalNAc-siRNAs are designed for targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR), but their interaction with plasma proteins can impact their bioavailability and efficacy.

Key Considerations in PPB Evaluation of GalNAc-siRNA

  1. Purpose of Plasma Protein Binding (PPB) Evaluation

    • Distribution: Determines the extent to which the siRNA is free in plasma vs. bound to proteins, impacting its availability for hepatocyte targeting.
    • Clearance: High protein binding often reduces renal clearance, prolonging circulation time, while low protein binding may lead to rapid clearance.
    • Efficacy and Safety: Protein binding influences the siRNA’s pharmacodynamic (PD) effect by modulating its free fraction available for receptor binding.

  2. Methodology for PPB Evaluation

    • Equilibrium Dialysis or Ultrafiltration: These techniques are used to assess the free (unbound) fraction of siRNA in plasma. Both methods are widely accepted, but each has distinct benefits:
      • Equilibrium Dialysis: This technique is highly effective for small molecules and siRNAs with lower protein binding. It involves separating free drug from bound drug across a semipermeable membrane.
      • Ultrafiltration: Useful for GalNAc-siRNAs if they exhibit high protein binding, as it allows quick separation of bound and unbound fractions.
    • Surface Plasmon Resonance (SPR) or Isothermal Titration Calorimetry (ITC): These are advanced methods used to directly characterize binding kinetics and affinity with specific plasma proteins, such as albumin.

  3. Common Plasma Proteins Binding GalNAc-siRNA

    • Albumin: Major protein in plasma, often binds GalNAc-conjugated molecules, which can stabilize and prolong circulation.
    • α-1 Acid Glycoprotein and Lipoproteins: Although they bind at lower affinities than albumin, they still contribute to overall PPB, especially in cases of variable protein levels (e.g., disease states).
    • Binding Affinity to ASGPR: Specific to GalNAc conjugates, which are designed for receptor-mediated endocytosis into hepatocytes, ensuring targeted liver delivery.

  4. Interpreting Results and Impact on PK/PD

    • High Protein Binding: When protein binding exceeds 95%, it suggests a smaller fraction of free siRNA in circulation, potentially reducing hepatocyte uptake and ASGPR interaction.
    • Moderate to Low Protein Binding: Greater free fraction may increase clearance and hepatocyte uptake, potentially enhancing therapeutic efficacy but reducing circulation time.
    • Target Organ Delivery: For GalNAc-siRNA, moderate PPB that allows selective ASGPR binding without excessive clearance is optimal for targeting hepatocytes.

  5. Challenges in PPB Evaluation of siRNA

    • Non-covalent Interactions: siRNA can have dynamic interactions with various plasma proteins that may vary based on formulation, conjugation, and physicochemical properties.
    • Stability: GalNAc-siRNAs must be stable in plasma for accurate PPB measurements, as degradation can skew results.
    • Method Sensitivity: As siRNAs are relatively large and complex molecules, sensitivity in detecting free vs. bound fractions is crucial to avoid underestimating protein binding.

Summary

The PPB evaluation of GalNAc-siRNAs is essential in understanding their distribution, clearance, and efficacy in hepatocyte targeting. Utilizing methods like equilibrium dialysis and ultrafiltration provides insights into binding dynamics, while interpreting binding data helps optimize dosing, therapeutic window, and targeted delivery to the liver 

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more